Clinical event rate in patients with and without left main disease undergoing isolated coronary artery bypass grafting: results from the European DuraGraft Registry.


Journal

European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
ISSN: 1873-734X
Titre abrégé: Eur J Cardiothorac Surg
Pays: Germany
ID NLM: 8804069

Informations de publication

Date de publication:
02 09 2022
Historique:
received: 18 02 2022
revised: 25 07 2022
accepted: 01 08 2022
pubmed: 6 8 2022
medline: 28 9 2022
entrez: 5 8 2022
Statut: ppublish

Résumé

Left main coronary artery disease (LMCAD) is considered an independent risk factor for clinical events after coronary artery bypass grafting (CABG). We have conducted a subgroup analysis of the multicentre European DuraGraft Registry to investigate clinical event rates at 1 year in patients with and without LMCAD undergoing isolated CABG in contemporary practice. Patients undergoing isolated CABG were selected. The primary end point was the incidence of a major adverse cardiac event (MACE) defined as the composite of death, myocardial infarction (MI) or repeat revascularization (RR) at 1 year. The secondary end point was major adverse cardiac and cerebrovascular events (MACCE) defined as MACE plus stroke. Propensity score matching was performed to balance for differences in baseline characteristics. LMCAD was present in 1033 (41.2%) and absent in 1477 (58.8%) patients. At 1 year, the MACE rate was higher for LMCAD patients (8.2% vs 5.1%, P = 0.002) driven by higher rates of death (5.4% vs 3.4%, P = 0.016), MI (3.0% vs 1.3%, P = 0.002) and numerically higher rates of RR (2.8% vs 1.8%, P = 0.13). The incidence of MACCE was 8.8% vs 6.6%, P = 0.043, with a stroke rate of 1.0% and 2.4%, P = 0.011, for the LMCAD and non-LMCAD groups, respectively. After propensity score matching, the MACE rate was 8.0% vs 5.2%, P = 0.015. The incidence of death was 5.1% vs 3.7%, P = 0.10, MI 3.0% vs 1.4%, P = 0.020, and RR was 2.7% vs 1.6%, P = 0.090, for the LMCAD and non-LMCAD groups, respectively. Less strokes occurred in LMCAD patients (1.0% vs 2.4%, P = 0.017). The MACCE rate was not different, 8.5% vs 6.7%, P = 0.12. In this large registry, LMCAD was demonstrated to be an independent risk factor for MACE after isolated CABG. Conversely, the risk of stroke was lower in LMCAD patients. ClinicalTrials.gov NCT02922088.

Identifiants

pubmed: 35929787
pii: 6656349
doi: 10.1093/ejcts/ezac403
pii:
doi:

Banques de données

ClinicalTrials.gov
['NCT02922088']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Investigateurs

Katharina Huenges (K)
Herko Grubitzsch (H)
Farhad Bakthiary (F)
Jörg Kempfert (J)
Adam J Penkalla (AJ)
Bernhard C Danner (BC)
Fawad A Jebran (FA)
Carina Benstoem (C)
Andreas Goetzenich (A)
Christian Stoppe (C)
Elmar W Kuhn (EW)
Oliver J Liakopoulos (OJ)
Stefan Brose (S)
Klaus Matschke (K)
Dave Veerasingam (D)
Kishore Doddakula (K)
Lorenzo Guerrieri Wolf (LG)
Giuseppe Filiberto Serraino (GF)
Pasquale Mastroroberto (P)
Nicola Lamascese (N)
Massimo Sella (M)
Edmundo R Fajardo-Rodriguez (ER)
Alejandro Crespo (A)
Angel L Fernandez Gonález (ALF)
Alvaro Pedraz (A)
Elena Arnáiz-García (E)
Ignacio Muñoz Carvajal (IM)
Adrian J Fontaine (AJ)
José Ramón González Rodríguez (JRG)
José Antonio Corrales Mera (JAC)
Paloma Martinez (P)
Jose Antonio Blazquez (JA)
Bella Ramirez (B)
Alejandro Adsuar-Gomez (A)
Jose M Borrego-Dominguez (JM)
Christian Muñoz-Guijosa (C)
Sara Badía-Gamarra (S)
Rafael Sádaba (R)
Alicia Gainza (A)
Manuel Castellá (M)
Gregorio Laguna (G)
Javier A Gualis (JA)
Stefanos Demertzis (S)
Jürg Grünenfelder (J)
Robert Bauernschmitt (R)
Amal K Bose (AK)
Nawwar Al-Attar (N)
George Gradinariu (G)

Commentaires et corrections

Type : CommentIn

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Auteurs

Etem Caliskan (E)

Charité Universitätsmedizin Berlin, Berlin, Germany.
German Heart Center Berlin, Berlin, Germany.

Martin Misfeld (M)

Leipzig Heart Center, Leipzig, Germany.
Royal Prince Alfred Hospital, Sydney, NSW, Australia.
Institute of Academic Surgery at RPA, Sydney, NSW, Australia.
The Baird Institute of Applied Heart and Lung Surgical Research, Sydney, NSW, Australia.
Medical School, University of Sydney, Sydney, NSW, Australia.

Sigrid Sandner (S)

Vienna General Hospital, Medical University of Vienna, Vienna, Austria.

Andreas Böning (A)

Universitätsklinikum Gießen und Marburg GmbH, Gießen, Germany.

Jose Aramendi (J)

Hospital de Cruces, Barakaldo, Spain.

Sacha P Salzberg (SP)

Swiss Heart Clinic, Zurich, Switzerland.

Yeong-Hoon Choi (YH)

Kerckhoff Heart Center Bad Nauheim, Campus Kerckhoff Justus-Liebig University Giessen, Bad Nauheim, Germany.

Louis P Perrault (LP)

Montreal Heart Institute, Montreal, QC, Canada.

Ilker Tekin (I)

Manavgat Government Hospital, Manavgat, Turkey.
Bahçeşehir University Faculty of Medicine, İstanbul, Turkey.

Gregorio P Cuerpo (GP)

Hospital General Universitario Gregorio Marañón, Madrid, Spain.

Jose Lopez-Menendez (J)

Hospital Universitario Ramon y Cajal, Madrid, Spain.

Luca P Weltert (LP)

European Hospital, Rome, Italy.

Johannes Böhm (J)

German Heart Center Munich, Munich, Germany.

Markus Krane (M)

German Heart Center Munich, Munich, Germany.
Yale University School of Medicine, New Haven, CT, USA.

José M González-Santos (JM)

Hospital Universitario de Salamanca, Salamanca, Spain.

Juan-Carlos Tellez (JC)

Hospital Universitario Virgen Macarena, Seville, Spain.

Tomas Holubec (T)

Goethe University Frankfurt and University Hospital Frankfurt, Frankfurt, Germany.

Enrico Ferrari (E)

Cardiocentro Ticino Institute, Lugano, Switzerland.
University of Zurich, School of Medicine, Zurich, Switzerland.

Maximilian Y Emmert (MY)

Charité Universitätsmedizin Berlin, Berlin, Germany.
German Heart Center Berlin, Berlin, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH